Eric Cantor Assumes New Role as President and CEO of PhRMA
Key Points
- Eric Cantor assumed his role November 9 as president and CEO of PhRMA, succeeding Stephen J. Ubl, who led the organization since 2015.
- Cantor, former U.S. House Majority Leader, represented Virginia from 2000 to 2014 and later served as vice chairman and managing director at Moelis & Company, a board seat he will retain.
- His priorities include expanding patient access to medicines, advancing AI to accelerate drug discovery, and supporting the U.S. biopharmaceutical workforce.
Former U.S. House Majority Leader Eric Cantor assumed his role on November 9 as president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA), succeeding Stephen J. Ubl, who has led the organization since 2015.
PhRMA says Cantor brings extensive experience in government, public policy, and global business at a time when the biopharmaceutical industry faces significant policy and regulatory challenges. Cantor represented Virginia in the U.S. House of Representatives from 2000 to 2014, serving as House Majority Leader during his final three years in Congress. His legislative work included advancing the Gabriella Miller Kids First Research Act, which directed federal research support toward pediatric diseases, and helping build support for Medicare Part D, which expanded prescription drug coverage for seniors and people with disabilities.
He also helped lay the groundwork for the bipartisan 21st Century Cures Act, which increased funding for the National Institutes of Health and introduced FDA reforms intended to accelerate the development and approval of new medicines.
Following his departure from Congress, Cantor joined Moelis & Company, where he serves as vice chairman and managing director, advising organizations on business strategy, mergers and acquisitions, public policy, and global economic issues. He will retain his seat on the company’s board while leading PhRMA.
Cantor said his priorities will include expanding patient access to medicines, advancing the use of artificial intelligence to accelerate drug discovery, and supporting the U.S. biopharmaceutical workforce.
Visit www.phrma.org for more information.
Total Page Views: 2
